Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
November 20, 2014
Interim Report – January to September 2014
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
Read more
August 22, 2014
Interim Report – January to June 2014
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its...
May 20, 2014
Interim Report – January to March 2014
February 20, 2014
Year End Report 2013
November 19, 2013
Interim Report – January to September 2013
August 29, 2013
Interim Report – January to June 2013
June 15, 2013
Interim Report – January to March 2013
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
August 7, 2012
Interim Report – January to June 2012
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...
